Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Veure altres versions (1)

BACKGROUND: For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years inste...

Descripció completa

Dades bibliogràfiques
Autors principals: Davies, C, Pan, H, Godwin, J, Gray, R, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, V, Badran, A, Bonfill, X, Bradbury, J, Clarke, M, Collins, R, Davis, SR, Delmestri, A, Forbes, J, Haddad, P, Hou, M, Inbar, M, Khaled, H, Kielanowska, J, Kwan, W, Mathew, B, Mittra, I, Müller, B
Format: Journal article
Idioma:English
Publicat: 2013

Ítems similars